BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27232265)

  • 1. A review of the venous thrombotic issues associated with multiple myeloma.
    Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
    Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
    Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
    Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.
    Leleu X; Rodon P; Hulin C; Daley L; Dauriac C; Hacini M; Decaux O; Eisemann JC; Fitoussi O; Lioure B; Voillat L; Slama B; Al Jijakli A; Benramdane R; Chaleteix C; Costello R; Thyss A; Mathiot C; Boyle E; Maloisel F; Stoppa AM; Kolb B; Michallet M; Lamblin A; Natta P; Facon T; Elalamy I; Fermand JP; Moreau P
    Thromb Haemost; 2013 Oct; 110(4):844-51. PubMed ID: 23903204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
    Uaprasert N; Voorhees PM; Mackman N; Key NS
    Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
    Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
    Al-Ani F; Bermejo JM; Mateos MV; Louzada M
    Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
    Singh A; Gajra A
    Cardiovasc Hematol Agents Med Chem; 2011 Jan; 9(1):7-13. PubMed ID: 20874693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.
    Kato A; Takano H; Ichikawa A; Koshino M; Igarashi A; Hattori K; Nagata K
    Thromb Res; 2013 Feb; 131(2):140-4. PubMed ID: 23232090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update of thrombosis in multiple myeloma.
    Leebeek FW
    Thromb Res; 2016 Apr; 140 Suppl 1():S76-80. PubMed ID: 27067983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].
    de Moreuil C; Ianotto JC; Eveillard JR; Carrier M; Delluc A
    Rev Med Interne; 2016 Jul; 37(7):473-9. PubMed ID: 26833146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
    Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
    Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations.
    Swan D; Rocci A; Bradbury C; Thachil J
    Br J Haematol; 2018 Nov; 183(4):538-556. PubMed ID: 30450656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
    Thaler J; Ay C; Pabinger I
    Thromb Haemost; 2012 Dec; 108(6):1042-8. PubMed ID: 22836491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
    Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT
    Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
    Bagratuni T; Kastritis E; Politou M; Roussou M; Kostouros E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanelias N; Terpos E; Dimopoulos MA
    Am J Hematol; 2013 Sep; 88(9):765-70. PubMed ID: 23757261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
    Hussein MA
    Thromb Haemost; 2006 Jun; 95(6):924-30. PubMed ID: 16732369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
    Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.